Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Dimethyl Fumarate in Early Relapsing-Remitting Multiple Sclerosis
NCT02746744Phase 3Completed
- Start
- May 2016
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in relapsing-remitting multiple sclerosis (RRMS), clinically isolated syndrome (CIS). Started May 2016; status: completed.
02
Drugs
rituximab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NCT02746744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02746744.